CD24

Summary

CD24 (CD24 molecule, HGNC:1645) is a protein-coding gene on chromosome 6q21, encoding Signal transducer CD24 (P25063). May have a pivotal role in cell differentiation of different cell types.

This gene encodes a sialoglycoprotein that is expressed on mature granulocytes and B cells and modulates growth and differentiation signals to these cells. The precursor protein is cleaved to a short 32 amino acid mature peptide which is anchored via a glycosyl phosphatidylinositol (GPI) link to the cell surface. This gene was missing from previous genome assemblies, but is properly located on chromosome 6. Non-transcribed pseudogenes have been designated on chromosomes 1, 15, 20, and Y. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 100133941 — RefSeq curated summary.

At a glance

• MANE Select transcript: NM_001359084

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1645
Approved symbol	CD24
Name	CD24 molecule
Location	6q21
Locus type	gene with protein product
Status	Approved
Aliases	CD24A
Ensembl gene	ENSG00000272398
Ensembl biotype	protein_coding
OMIM	600074
Entrez	100133941

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000606017, ENST00000610952, ENST00000615659, ENST00000619133, ENST00000619869, ENST00000620405, ENST00000621311, ENST00000622315

RefSeq mRNA: 5 — MANE Select: NM_001359084 NM_001291737, NM_001291738, NM_001291739, NM_001359084, NM_013230

CCDS: CCDS75499, CCDS78166

Canonical transcript exons

ENST00000606017 — 2 exons

Exon	Start	End
ENSE00003696480	106974578	106974729
ENSE00003891022	106969831	106971834

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 99.94.

FANTOM5 (CAGE): breadth broad, TPM avg 152.2837 / max 6846.6717, expressed in 902 samples.

FANTOM5 promoters (16 alternative TSS)

Promoter ID	TPM avg	Samples expressed
204130	146.7120	521
204132	2.2038	686
204123	0.5036	198
204131	0.4516	189
204128	0.4148	192
204138	0.3647	100
204135	0.3303	193
204122	0.2894	145
204133	0.2506	154
204134	0.1971	130

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	99.94	gold quality
renal medulla	UBERON:0000362	99.94	gold quality
epithelium of bronchus	UBERON:0002031	99.92	gold quality
bronchus	UBERON:0002185	99.91	gold quality
colonic mucosa	UBERON:0000317	99.90	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.88	gold quality
esophagus squamous epithelium	UBERON:0006920	99.88	gold quality
oral cavity	UBERON:0000167	99.87	gold quality
parotid gland	UBERON:0001831	99.86	gold quality
squamous epithelium	UBERON:0006914	99.86	gold quality
gingiva	UBERON:0001828	99.85	gold quality
gingival epithelium	UBERON:0001949	99.85	gold quality
epithelium of nasopharynx	UBERON:0001951	99.84	gold quality
epithelial cell of pancreas	CL:0000083	99.82	gold quality
ileal mucosa	UBERON:0000331	99.82	gold quality
tongue squamous epithelium	UBERON:0006919	99.81	gold quality
pharyngeal mucosa	UBERON:0000355	99.79	gold quality
gall bladder	UBERON:0002110	99.79	gold quality
cortical plate	UBERON:0005343	99.79	gold quality
oviduct epithelium	UBERON:0004804	99.78	gold quality
cervix squamous epithelium	UBERON:0006922	99.78	gold quality
pancreatic ductal cell	CL:0002079	99.77	gold quality
mucosa of transverse colon	UBERON:0004991	99.76	gold quality
seminal vesicle	UBERON:0000998	99.75	gold quality
nasal cavity epithelium	UBERON:0005384	99.75	gold quality
thyroid gland	UBERON:0002046	99.73	gold quality
left lobe of thyroid gland	UBERON:0001120	99.71	gold quality
metanephros cortex	UBERON:0010533	99.71	gold quality
lower esophagus mucosa	UBERON:0035834	99.71	gold quality
embryo	UBERON:0000922	99.69	gold quality

Single-cell (SCXA)

Detected in 64 experiment(s), a significant marker in 56.

Experiment	Marker?	Max mean expression
E-MTAB-10885	yes	5784.88
E-HCAD-1	yes	4576.50
E-GEOD-114530	yes	4125.75
E-MTAB-10855	yes	4114.86
E-MTAB-5061	yes	3974.37
E-GEOD-93593	yes	3441.01
E-MTAB-8142	yes	3168.29
E-GEOD-86618	yes	3157.62
E-GEOD-124472	yes	2994.88
E-GEOD-125970	yes	2850.15
E-MTAB-10596	yes	2797.27
E-CURD-7	yes	2577.22
E-CURD-112	yes	2303.71
E-HCAD-10	yes	2163.48
E-CURD-88	yes	2153.14

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, ESR1, GLI1, HIF1A, HLX, HOXC11, JUN, KDM5A, MBD2, NCOA1, NFAT5, NR1H3, SATB2, STAT5A, TCF4, TCF7L2, TWIST1, TWIST2

miRNA regulators (miRDB)

73 targeting CD24, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-12136	99.98	72.81	5713
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-26A-1-3P	99.64	66.81	788
HSA-MIR-26A-2-3P	99.64	66.82	786
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-6758-3P	99.57	67.55	1078

Literature-anchored findings (GeneRIF, showing 40)

• The correlation between CD24 expression and invasiveness was calculated to be highly significant (PMID:12218294)
• is expressed in ovarian cancer and is a new independent prognostic marker of patient survival (PMID:12368195)
• assessment of expression on bone marrow neutrophilic granulocytes: a marker for myelocytic leukemia staging (PMID:12447971)
• CD24 mediates apoptosis in precursor-B acute lymphoblastic leukemia cell lines in the pro-B and pre-B stages accompanying activation of multiple caspases. (PMID:12496407)
• high level of CD24 expression is associated with nonsmall cell lung cancer (PMID:12610508)
• N-glycans of the mouse glycoprotein HSA and its human analogue CD24 from lymphoblastoma, neuroblastoma and astrocytoma cell lines as well as from mouse brain homogenate were analysed and compared to each other (PMID:12829373)
• Deficiency in function of the CD4(+)CD25(+) T-cell population may influence the pathogenesis of type 1 diabetes. (PMID:15616015)
• Overexpression of CD24 is associated with intrahepatic cholangiocarcinoma (PMID:16125303)
• CD24 constitutes an important molecular marker for various epithelial neoplasms (PMID:16164042)
• CD24 is commonly up-regulated in colorectal cancer and is a new independent prognostic marker. (PMID:16166435)
• CD24 expression was upregulated in chordoma, while it was absent in chondrosarcoma (PMID:16288985)
• CD80-CD24 molecule spontaneously incorporated onto cell membrane through its glycolipid anchor suggesting that this hybrid costimulatory molecule can be used in protein transfer to develop effective cancer vaccines (PMID:16621031)
• Over-expression of CD24 is associated with primary and relapsed ovarian cancer (PMID:16681720)
• CD24 is overexpressed in the colonic mucosa, already at an early stage of carcinogenesis. It may be a useful target for early detection and in CRC therapy. (PMID:16890615)
• The study documented that cytoplasmic-membranous expression of CD24 represented an extremely strong unfavourable prognostic factor in breast cancer. (PMID:16892043)
• association between the V/V genotype at aa 57 of this gene and multiple sclerosis in Basque natives (PMID:16900767)
• CD24 regulates E-cadherin and TGF-beta3 expression in cultured oral epithelial cells (PMID:16930538)
• A destabilizing dinucleotide deletion in the 3’ UTR of CD24 mRNA conveys significant protection against both multiple sclerosis and systemic lupus erythematosus. (PMID:17411341)
• CD24 is modulated by IGFBP-2 and contributes to IGFBP-2-enhanced invasiveness of glioblastoma cells (PMID:17475624)
• CD24 deficient breast cancer cells are successful in overcoming an engraftment incompatibility that exists when injecting human cells into mouse adipose tissue. (PMID:17540049)
• CD24 is not essential for exosome formation or release but may be a convenient exosome marker. Our studies suggest that exosomal secretion from the embryonic kidney could play a biological role at the fetal-maternal interphase. (PMID:17700640)
• findings suggest that the CD24 A57V polymorphism plays a role in susceptibility to systemic lupus erythematosus in a Spanish population (PMID:17763438)
• Study identifies CD24 and EpCAM as cargo proteins of exosomes of cultured ovarian cancer cell lines and malignant ascites. (PMID:17900673)
• A decrease in CD4+CD25+ T cell numbers in mitral stenosis patients might suggest a role for cellular autoimmunity in a smoldering rheumatic process. (PMID:17944116)
• High CD24 is associated with neoplasm invasiveness in breast cancer (PMID:17950993)
• CD24 acts as a gate-keeper for lipid rafts, thereby regulating the activity of integrins and other proteins (PMID:17980703)
• There is a potential role for the CD24 gene in the susceptibility to giant cell arteritis in our population in Spain. (PMID:18381780)
• CD24 expression in clear cell renal cell carcinoma may be associated with high nuclear grade, large tumor size, and shortened progression-free survival (PMID:18384848)
• CD24 is repressed by estrogen and this repression is a direct transcriptional effect depending on ER alpha and histone deacetylases. (PMID:18404683)
• As a putative new oncogene that is overexpressed in gastrointestinal malignancies early in the carcinogenesis process, CD24 my be a potential target for early intervention in the prevention and treatment of cancer. (PMID:18413748)
• low expression of CD24 may cause the enhanced immune reaction and could play a role in the abnormal development of placenta in pre-eclampsia (PMID:18417991)
• In breast tissue, CD44(+)/CD24(-/low) tumor cells seem to be associated with lack of lymph node metastasis and a tendency toward an increase of the relapse-free survival of the patients. (PMID:18495204)
• analysis of CD44 and CD24 expression in breast tumors (PMID:18559090)
• MOG specific T cells (2D2) will escape clonal deletion and can result in spontaneous EAE. CD24 deficient MOG specific T cells (2D2CD24KO) are depleted from the thymic compartment, and the T cells in the periphery are CD4 negative. (PMID:18566397)
• CD44 but not CD24 may be involved in the breast cancer pathway and is a target for oncolytic virotherapy (PMID:18632604)
• Overexpression of CD24 is associated with prostate cancer. (PMID:18752058)
• Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater. (PMID:19043399)
• Overexpression of CD24 is associated with esophageal squamous cell carcinoma. (PMID:19050962)
• CD24 appears to be highly expressed in a large variety of human cancers and to contribute to the acceleration of tumor growth and metastases shedding by binding to platelet (P)-selectin (PMID:19072375)
• Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium are reported. (PMID:19130400)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cd24a	ENSMUSG00000047139
rattus_norvegicus	Cd24	ENSRNOG00000000321

Protein

Protein identifiers

Signal transducer CD24 — P25063 (reviewed: P25063)

Alternative names: Small cell lung carcinoma cluster 4 antigen

All UniProt accessions (4): A0A087WU21, A0A087WU87, A0A087WW33, P25063

UniProt curated annotations — full annotation on UniProt →

Function. May have a pivotal role in cell differentiation of different cell types. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Modulates B-cell activation responses. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells. In association with SIGLEC10 may be involved in the selective suppression of the immune response to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70 and HSP90. Plays a role in the control of autoimmunity.

Subunit / interactions. Interacts with LYN and FGR in a cell-type specific manner. Binds FRG in a small cell cancer line, LYN in the erythroleukemia cell line K-562 and in Burkitt’s lymphoma.

Subcellular location. Cell membrane.

Tissue specificity. B-cells. Expressed in a number of B-cell lines including P32/ISH and Namalwa. Expressed in erythroleukemia cell and small cell lung carcinoma cell lines. Also expressed on the surface of T-cells.

Post-translational modifications. Extensively O-glycosylated.

Disease relevance. Multiple sclerosis (MS) [MIM:126200] A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Disease susceptibility may be associated with variants affecting the gene represented in this entry.

Induction. Expression is lost when primary B-cells are induced to differentiate in antibody-forming cells.

Similarity. Belongs to the CD24 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P25063-1	1	yes
P25063-2	2

RefSeq proteins (5): NP_001278666, NP_001278667, NP_001278668, NP_001346013, NP_037362 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028029	CD24	Family

Pfam: PF14984

UniProt features (12 total): sequence conflict 2, glycosylation site 2, sequence variant 2, signal peptide 1, peptide 1, propeptide 1, region of interest 1, lipid moiety-binding region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P25063-F1	64.49	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 59

Glycosylation sites (2): 36, 52

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-373760	L1CAM interactions
R-HSA-9927418	Developmental Lineage of Mammary Gland Luminal Epithelial Cells
R-HSA-9927426	Developmental Lineage of Mammary Gland Alveolar Cells
R-HSA-1266738	Developmental Biology
R-HSA-422475	Axon guidance
R-HSA-9675108	Nervous system development

MSigDB gene sets: 401 (showing top): GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_CELL_ACTIVATION, MODULE_52, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, LOPEZ_MESOTHELIOMA_SURVIVAL_DN, GOBP_EPITHELIUM_DEVELOPMENT, TSENG_IRS1_TARGETS_UP, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_RESPONSE_TO_PEPTIDE, GOBP_STEROL_HOMEOSTASIS, JAEGER_METASTASIS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_LYMPHOCYTE_COSTIMULATION, GOCC_CELL_SURFACE, GOBP_KIDNEY_EPITHELIUM_DEVELOPMENT

GO Biological Process (25): response to hypoxia (GO:0001666), cell activation (GO:0001775), regulation of cytokine-mediated signaling pathway (GO:0001959), response to molecule of bacterial origin (GO:0002237), immune response-regulating cell surface receptor signaling pathway (GO:0002768), positive regulation of cytosolic calcium ion concentration (GO:0007204), Wnt signaling pathway (GO:0016055), cell migration (GO:0016477), regulation of cell-cell adhesion (GO:0022407), regulation of epithelial cell differentiation (GO:0030856), T cell costimulation (GO:0031295), B cell receptor transport into membrane raft (GO:0032597), chemokine receptor transport out of membrane raft (GO:0032600), negative regulation of transforming growth factor beta3 production (GO:0032913), positive regulation of activated T cell proliferation (GO:0042104), cholesterol homeostasis (GO:0042632), regulation of MAPK cascade (GO:0043408), response to estrogen (GO:0043627), respiratory burst (GO:0045730), podocyte differentiation (GO:0072112), glomerular parietal epithelial cell differentiation (GO:0072139), intrinsic apoptotic signaling pathway (GO:0097193), cell-cell adhesion (GO:0098609), positive regulation of nephron tubule epithelial cell differentiation (GO:2000768), cell adhesion (GO:0007155)

GO Molecular Function (3): protein kinase binding (GO:0019901), protein tyrosine kinase activator activity (GO:0030296), protein binding (GO:0005515)

GO Cellular Component (6): external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020), membrane raft (GO:0045121), plasma membrane (GO:0005886), side of membrane (GO:0098552)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Developmental Lineages of the Mammary Gland	2
Axon guidance	1
Nervous system development	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell surface receptor signaling pathway	2
membrane	2
response to stress	1
response to decreased oxygen levels	1
cellular process	1
multicellular organismal process	1
regulation of signal transduction	1
cytokine-mediated signaling pathway	1
regulation of response to cytokine stimulus	1
response to bacterium	1
response to external biotic stimulus	1
immune response-regulating signaling pathway	1
regulation of biological quality	1
cell motility	1
regulation of cell adhesion	1
cell-cell adhesion	1
epithelial cell differentiation	1
regulation of cell differentiation	1
regulation of multicellular organismal development	1
lymphocyte costimulation	1
positive regulation of T cell activation	1
B cell receptor transport within lipid bilayer	1
protein transport into membrane raft	1
protein transport out of membrane raft	1
chemokine receptor transport within lipid bilayer	1
transforming growth factor beta3 production	1
regulation of transforming growth factor beta3 production	1
negative regulation of transforming growth factor beta production	1
positive regulation of T cell proliferation	1
regulation of activated T cell proliferation	1
activated T cell proliferation	1
sterol homeostasis	1
MAPK cascade	1
regulation of intracellular signal transduction	1
response to hormone	1
metabolic process	1
renal filtration cell differentiation	1
glomerular epithelial cell differentiation	1
kinase binding	1

Protein interactions and networks

STRING

2672 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD24	SIGLEC10	Q96LC7	998
CD24	SELP	P16109	994
CD24	HMGB1	P09429	991
CD24	CD44	P16070	899
CD24	SELE	P16111	892
CD24	EPCAM	P16422	883
CD24	SIRPA	P78324	880
CD24	PROM1	O43490	877
CD24	L1CAM	P32004	849
CD24	PECAM1	P16284	848
CD24	ALDH1A1	P00352	815
CD24	EGFR	P00533	806
CD24	CD19	P15391	785
CD24	CD38	P28907	784
CD24	PTPRC	P08575	780

IntAct

8 interactions, top by confidence:

A	B	Type	Score
LYN	CD24	psi-mi:“MI:0914”(association)	0.500
CD24	LYN	psi-mi:“MI:0915”(physical association)	0.500
LYN	CD24	psi-mi:“MI:0915”(physical association)	0.500
CD24	SELP	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (8): NPM1 (Affinity Capture-MS), NPM1 (Affinity Capture-Western), CD24 (Affinity Capture-Western), CD24 (Reconstituted Complex), FGR (Affinity Capture-Western), LYN (Affinity Capture-Western), SELP (Reconstituted Complex), CD24 (Affinity Capture-MS)

ESM2 similar proteins: A0MLS4, A2BDG0, A2BDG5, A2BDG9, A2RRL7, A3KN25, A6NGB7, G1TZA0, O14669, O77751, O77801, O95868, P01286, P02820, P02822, P0DUJ6, P24807, P25063, P27177, P41547, P51460, P63292, P98162, Q01524, Q08DF2, Q1ECT8, Q1JPW9, Q496H8, Q58CU5, Q5CZK3, Q5G860, Q5G863, Q5HZE8, Q60549, Q64697, Q6BEG6, Q7TPG6, Q8C4W3, Q8R182, Q923S2

Diamond homologs: P24807, P25063, Q07490

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000269633 (6:106974081 C>G), RS1000635744 (6:106978818 G>A), RS1000863675 (6:106972628 G>A,C), RS1001358454 (6:106972304 T>C), RS1001642494 (6:106977427 C>T), RS1001878252 (6:106977711 G>A), RS1002643925 (6:106975919 T>C), RS1002884827 (6:106976211 T>C), RS1003742204 (6:106974596 T>C), RS1004117417 (6:106974414 G>A), RS1004717298 (6:106973243 T>G), RS1005151730 (6:106973455 G>C), RS1005537113 (6:106977769 C>T), RS1005750198 (6:106969755 A>T), RS1005784275 (6:106978028 A>G,T)

Disease associations

OMIM: gene MIM:600074 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

CTD chemical–gene interactions

103 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, affects cotreatment, increases abundance	5
methylmercuric chloride	increases expression, affects cotreatment	4
Estradiol	affects cotreatment, decreases expression	4
bisphenol A	increases expression	3
trichostatin A	affects cotreatment, increases expression	3
Valproic Acid	affects cotreatment, increases expression, affects expression	3
arsenite	affects binding, increases reaction, decreases methylation	2
cobaltous chloride	decreases expression, increases expression, decreases reaction	2
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Decitabine	decreases expression, decreases reaction, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Calcitriol	increases expression, affects cotreatment	2
Progesterone	affects cotreatment, decreases expression	2
Smoke	decreases expression, decreases reaction	2
Tobacco Smoke Pollution	decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
aristolochic acid I	decreases expression	1
napabucasin	decreases expression	1
triptolide	decreases reaction, increases expression	1
methylparaben	increases expression	1
afimoxifene	increases expression	1
sulforaphane	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
ochratoxin A	decreases expression	1
didecyldimethylammonium	decreases expression	1
potassium chromate(VI)	decreases expression	1
rutecarpine	decreases expression	1
ferrous chloride	increases expression	1

Cellosaurus cell lines

10 cell lines: 9 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E6PD	Genomeditech CHO-K1 H_CD24	Spontaneously immortalized cell line	Female
CVCL_E6WB	Genomeditech MC-38 H_CD24	Cancer cell line	Female
CVCL_SH60	HAP1 CD24 (-) 1	Cancer cell line	Male
CVCL_SH61	HAP1 CD24 (-) 2	Cancer cell line	Male
CVCL_SH62	HAP1 CD24 (-) 3	Cancer cell line	Male
CVCL_SH63	HAP1 CD24 (-) 4	Cancer cell line	Male
CVCL_SH64	HAP1 CD24 (-) 5	Cancer cell line	Male
CVCL_SH65	HAP1 CD24 (-) 6	Cancer cell line	Male
CVCL_SH66	HAP1 CD24 (-) 7	Cancer cell line	Male
CVCL_SH67	HAP1 CD24 (-) 8	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.